Veliflapon

Veliflapon (BAY X 1005; DG-031) is an orally active and selective 5-lipoxygenase activating protein (FLAP) inhibitor[1]. Veliflapon inhibits the synthesis of the leukotrienes B4 and C4[2].

Product Specifications

CAS Number

[128253-31-6]

Product Name Alternative

BAY X 1005; DG-031

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

FLAP; Leukotriene Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/veliflapon.html

Purity

99.31

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)[C@H](C1CCCC1)C(C=C2)=CC=C2OCC3=NC4=CC=CC=C4C=C3

Molecular Formula

C23H23NO3

Molecular Weight

361.43

Precautions

H302, H315, H319, H335

References & Citations

[1]Müller-Peddinghaus R, et al. BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. J Pharmacol Exp Ther. 1993 Oct;267 (1) :51-7.|[2]Fruchtmann R, et al. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions. 1993 Mar;38 (3-4) :188-95.|[3]Jawień J, et al. BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58 (3) :583-8.|[4]Hatzelmann A, et al. Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase. Agents Actions. 1994 Nov;43 (1-2) :64-8.